What's Hot

View all perspectives
      RT @AurelieRheumo: Peresolimab PD-1 agonist in RA Phase 2 RCT

      Primary endpoint met w/ > improvement DAS28CRP Wk12

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      Peresolimab PD-1 agonist in RA Phase 2 RCT Primary endpoint met w/ > improvement DAS28CRP Wk12 Also greater improvement of CDAI in both treated grps TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg https://t.co/QtclWIWAw9 Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt
      RT @RichardPAConway: Wipfler et al. Characteristics refractory RA. Associations at baseline (A) and follow-up (B) @Rheum

      Richard Conway RichardPAConway

      2 years 5 months ago
      Wipfler et al. Characteristics refractory RA. Associations at baseline (A) and follow-up (B) @RheumNow #ACR22 Abstr#1952 https://t.co/4PJtrDp3Ba https://t.co/x1NCq07Y1h
      RT @RichardPAConway: Rossato et al. Women in highest tertile ultra-processed food intake 50% more likely to develop SLE

      Richard Conway RichardPAConway

      2 years 5 months ago
      Rossato et al. Women in highest tertile ultra-processed food intake 50% more likely to develop SLE than those in lowest tertile. Exacerbated by high BMI. @RheumNow #ACR22 Abstr#1634 https://t.co/T4Bx59VJPX https://t.co/oWaj9QbzgY
      RT @EBRheum: Important late breaker re:barriers to MTX post Roe decision

      6% of respondents who tried to fill MTX had ba

      Mike Putman EBRheum

      2 years 5 months ago
      Important late breaker re:barriers to MTX post Roe decision 6% of respondents who tried to fill MTX had barriers to access; most commonly related to pharmacies/pharmacists This number should be 0%!! #ACR22 abstr#L09 @RheumNow https://t.co/dgZkJLlL25
      RT @RHEUMarampa: Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over th

      sheila RHEUMarampa

      2 years 5 months ago
      Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over the 3-yr treatment period in pts with #lupus nephritis #ACR22 @RheumNow ABST#1653 https://t.co/C4n6Yb8bdC
      RT @RichardPAConway: Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout sugg

      Richard Conway RichardPAConway

      2 years 5 months ago
      Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout suggest ongoing NLRP3 inflammasome activity between gout attacks. @RheumNow #ACR22 Abstr#1808 https://t.co/OnJOpkRqH9 https://t.co/TGd6pn8Lne
      RT @KDAO2011: "FRAX should be done even if DXA T-2.5 score as it will tell you the probability of fracture in the next 1

      TheDaoIndex KDAO2011

      2 years 5 months ago
      "FRAX should be done even if DXA T-2.5 score as it will tell you the probability of fracture in the next 10 years" - Dr. M Humphrey Dr. B Humphrey #ACR22 #Osteoporosis Guidelines Session @rheumnow
      RT @RichardPAConway: Adami et al. GCs as low as 2.5mg/day assoc bone loss in RMD. Preventable with anti-resporptives. GC

      Richard Conway RichardPAConway

      2 years 5 months ago
      Adami et al. GCs as low as 2.5mg/day assoc bone loss in RMD. Preventable with anti-resporptives. GC>=5mg/day aHR 2.37 for fracture @RheumNow #ACR22 Abstr#L01 https://t.co/1Q8dDarcAB https://t.co/dW4glkerAL
      RT @RichardPAConway: Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expecte

      Richard Conway RichardPAConway

      2 years 5 months ago
      Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expected, ?need for screening pre-allopurinol? @RheumNow #ACR22 Abstr#1793 https://t.co/KrsjQ836BY https://t.co/bmPyqQi7OF
      RT @KDAO2011: #ACR22 #Osteoporosis Guidelines Case Example:
      The FRAX score needs to be adjusted (multiply by 1.15 or 1.2

      TheDaoIndex KDAO2011

      2 years 5 months ago
      #ACR22 #Osteoporosis Guidelines Case Example: The FRAX score needs to be adjusted (multiply by 1.15 or 1.2) in pts who are expected to have cumulative dose >5 grams/year of steroids @rheumnow https://t.co/wF8LP0iZjw
      RT @drdavidliew: Steroid-sparing in PMR: methotrexate most used, but what is the evidence?

      Christian Dejaco says: varia

      David Liew drdavidliew

      2 years 5 months ago
      Steroid-sparing in PMR: methotrexate most used, but what is the evidence? Christian Dejaco says: variable at best. We need a proper RCT - and it’s on its way. @Sarah_L_Mackie @profbdasgupta @DrMaxYates1 @CatherineL_Hill @drceowen #ACR22 @RheumNow https://t.co/dxaPdVcOPQ
      RT @synovialjoints: Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a hi

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a history of artherosclerotic CV disease (ASCVD). CV risk (MACE-8 with HF +VTE) was higher in the Tofa 10mg bd vs TNFi. Buch M #L06 https://t.co/lFXl2ywbZe #ACR22 @RheumNow
      RT @RichardPAConway: Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcome

      Richard Conway RichardPAConway

      2 years 5 months ago
      Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt
      RT @AurelieRheumo: Systemic Inflammation Index (neutrophils*platelet count/lymphocyte count)
      predicts survival in RA in

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      Systemic Inflammation Index (neutrophils*platelet count/lymphocyte count) predicts survival in RA in 1000+ pts All cause mortality OR 2.64 CV-mortality OR 3.03 Another proof (if needed) of asso inflammation & mortality in RA https://t.co/A77iPTTfTM Abs#1650 #ACR22 @RheumNow https://t.co/8aHYAZEg6v
      RT @RHEUMarampa: Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the

      sheila RHEUMarampa

      2 years 5 months ago
      Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target. #ACR22 @Rheumnow @rheumarhyme @trishiemd https://t.co/GjLt2Nym3I

      Podcasts

      • Keys to Mastery (5.2.2025)
      • A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis Sponsored by AbbVie Medical Affairs + Health Impact
      • Rheumatology Believe It or Not (4.25.2025)

      Catch up on Conference Podcasts

      ×